NexImmune, Inc. has announced a Special Meeting of Stockholders to vote on the company's dissolution and subsequent liquidation, following a series of adjournments due to insufficient quorum. The meeting, to be held virtually, is set for 2024, with the exact date and time to be announced. The Board has recommended the dissolution due to the company's inability to secure additional financing and limited alternatives to maximize value. The proposal, if approved, will authorize the Board to liquidate and wind up the company's affairs. Despite more votes for dissolution than against in previous adjournments, the necessary quorum was not met. The company had previously entered into an agreement to sell common stock and warrants for approximately $3.67 million, postponing the...Show More

NexImmune, Inc. has announced a Special Meeting of Stockholders to vote on the company's dissolution and subsequent liquidation, following a series of adjournments due to insufficient quorum. The meeting, to be held virtually, is set for 2024, with the exact date and time to be announced. The Board has recommended the dissolution due to the company's inability to secure additional financing and limited alternatives to maximize value. The proposal, if approved, will authorize the Board to liquidate and wind up the company's affairs. Despite more votes for dissolution than against in previous adjournments, the necessary quorum was not met. The company had previously entered into an agreement to sell common stock and warrants for approximately $3.67 million, postponing the special meeting while exploring other options. However, additional financing efforts have not been successful. The Board has issued one share of Series A Preferred Stock to ensure a quorum for the upcoming vote, assuming the preferred stock votes in favor of the proposal. The Board has also reviewed the dissolution in light of the company's financial position and lack of revenue, deeming it advisable and in the best interests of the company and its stockholders.